Antibody-Drug Conjugates (ADC) Preparation Research Reagents (577)

ADC drugs are targeted therapies created by connecting monoclonal antibodies with small molecule toxin drugs via linkers. They are composed of three key elements: antibodies, small molecule toxins, and linkers. Each component must possess specific characteristics. The antibody should exhibit high specificity and low immunogenicity; the linker must remain stable within the circulatory system while efficiently releasing cytotoxins in the tumor microenvironment; and the small molecule toxin should be stable under physiological conditions and exhibit potent lethality toward tumor cells. An ideal ADC drug should maintain stability in blood circulation, precisely target the treatment site, and ultimately release cytotoxic agents near the target.